Correction of erythrocyte deformability defect in ALX-induced diabetic rabbits after treatment with aminoguanidine.
To test whether treatment with aminoguanidine, a drug known to prevent cross-linking between glycated proteins, is effective in improving reduced erythrocyte deformability in diabetes, we studied a group (n = 6) of ALX-induced long-term (12.7 +/- 2.2 mo of hyperglycemia) diabetic New Zealand white rabbits before and after 20 wk of treatment with aminoguanidine (100 mg.kg-1 x day-1). The key findings were as follows: 1) at 12 wk of treatment with aminoguanidine, mean erythrocyte deformability normalized and remained within the normal reference range throughout the period of aminoguanidine administration; 2) 10 wk after discontinuing aminoguanidine in a subset of diabetic rabbits, mean erythrocyte deformability deteriorated by approximately 50%; 3) blood glucose and total GHb did not vary significantly during treatment with aminoguanidine nor after its discontinuation.
Brown
C D
CD
State University of New York Health Science Center, Brooklyn.
Zhao
Z H
ZH
De Alvaro
F
F
Chan
S
S
Friedman
E A
EA
D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D003921:Diabetes Mellitus, Experimental / Q000097:blood* / Q000188:drug therapy*; D004907:Erythrocyte Deformability / Q000187:drug effects*; D006146:Guanidines / Q000627:therapeutic use*; D008297:Male; D011817:Rabbits; D012016:Reference Values; D013997:Time Factors
D001786:Blood Glucose; D006146:Guanidines; C004479:pimagedine